



CEO shakeup at San Antonio biotech company StemBioSys

StemBioSys CEO Peter Savas is returning to Boston because of family reasons and will be replaced on an interim basis by John Feik.

StemBioSys Inc. (SBS), a San Antonio-based biomedical company that is working to advance stem cell technologies, has named [John W. Feik](#) as its interim CEO.

Feik replaces [Peter Savas](#), who relocated to San Antonio from Boston and was named CEO of privately held SBS last year. Savas is returning to Boston for family reasons, SBS officials say.

SBS gained some important momentum under Savas leadership. The company's chairman, Dr. [Steven A. Davis](#), points out that on Savas watch, SBS strengthened its technology and patent portfolios, entered into ongoing collaborations with regenerative medicine experts at [MIT](#) in Cambridge, Mass., and with BioBridge Global in San Antonio.

SBS also secured new funding from public and private sources with Savas at the helm.

Feik, who is a member of the SBS board of directors, has more than 35 years of experience in the pharmaceutical industry. He served as president and chief operating officer for [DFB Pharmaceuticals](#) Inc., the parent company of DPT Laboratories, until it was acquired by [Smith & Nephew](#) in 2013.

Feik, who is a native of San Antonio, will lead SBS until the company secures a permanent CEO.

"We are thrilled to have someone of (Feik's) stature and experience as our interim CEO during this key period of transition and growth," Davis says. "As one of San Antonio's most accomplished bioscience executives and entrepreneurs, John has led his companies to great success in the manufacture and marketing of FDA-approved therapeutic products for human use. His special expertise in regenerative medicine and his management skills are a huge plus for SBS as we move to target clinical applications and commercialize our innovative technologies."

Says Feik, "I'm very excited about the groundbreaking technology we are developing at StemBioSys. That technology and the people around it are what attracted me to invest in the company in the first place."